The combination therapy showed an enhanced tumor immune infiltration compared with anti-PD-1 therapy alone, albeit no further enhancement compared with ZD55-IL-24 therapy alone (Fig. 2d, h). This evidence concerns the gene PDCD1 and neoplasm.